ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 166 filers reported holding ESPERION THERAPEUTICS INC NE in Q1 2019. The put-call ratio across all filers is 1.82 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,219,072 | +273.2% | 2,264,359 | +429.3% | 0.01% | +333.3% |
| Q2 2023 | $594,631 | +140.5% | 427,792 | +175.1% | 0.00% | +50.0% |
| Q1 2023 | $247,250 | -72.8% | 155,503 | +6.5% | 0.00% | -66.7% |
| Q4 2022 | $909,699 | -0.3% | 146,019 | +316.3% | 0.01% | -25.0% |
| Q4 2020 | $912,000 | -29.8% | 35,072 | +0.3% | 0.01% | -38.5% |
| Q3 2020 | $1,299,000 | -34.5% | 34,952 | -9.5% | 0.01% | -38.1% |
| Q2 2020 | $1,982,000 | +64.8% | 38,620 | +1.2% | 0.02% | +40.0% |
| Q1 2020 | $1,203,000 | -51.1% | 38,159 | -7.5% | 0.02% | -37.5% |
| Q4 2019 | $2,460,000 | +107.8% | 41,247 | +27.7% | 0.02% | +60.0% |
| Q3 2019 | $1,184,000 | -18.0% | 32,310 | +4.1% | 0.02% | -25.0% |
| Q2 2019 | $1,444,000 | +13.3% | 31,050 | -2.1% | 0.02% | +11.1% |
| Q1 2019 | $1,274,000 | +239.7% | 31,720 | +289.2% | 0.02% | +157.1% |
| Q4 2018 | $375,000 | +7.8% | 8,150 | +3.8% | 0.01% | +40.0% |
| Q3 2018 | $348,000 | +11.2% | 7,850 | -57.6% | 0.01% | -28.6% |
| Q1 2016 | $313,000 | – | 18,500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 4,468,835 | $27,840,842 | 18.82% |
| Ikarian Capital, LLC | 1,891,147 | $11,781,846 | 2.84% |
| Altium Capital Management LP | 620,000 | $3,862,600 | 1.96% |
| Ikarian Capital, LLC | 1,296,900 | $8,079,687 | 1.95% |
| Parkman Healthcare Partners LLC | 822,784 | $5,125,944 | 1.36% |
| Deep Track Capital, LP | 4,000,000 | $24,920,000 | 1.05% |
| Monaco Asset Management SAM | 470,100 | $2,928,723 | 0.88% |
| BRAIDWELL LP | 3,393,405 | $21,140,913 | 0.71% |
| Telemetry Investments, L.L.C. | 71,000 | $442 | 0.70% |
| Rhenman & Partners Asset Management AB | 900,000 | $5,607,000 | 0.58% |